Pharma

Your Article Summary

See Latest Articles

Antigenics' Oncophage Cancer Vaccine Receives European Orphan Drug Designation for Brain Cancer
Antigenics, 04/30/09

Antigenics Inc. announced that Oncophage has been granted a positive recommendation for orphan drug designation for the treatment of glioma by the Committee for Orphan Medical Products (COMP) of the European Medicines Agency (EMEA). This designation provides Antigenics with, among other benefits, 10 years of potential market exclusivity if the product is approved for marketing in the European Union.

Today in Drug/Product Approvals...keeping you current

Receive free subspecialty "5-minute updates" via email

Telmisartan/amlodipine: approved for high blood pressure
Formulary , 12/16/09

Eslicarbazepine: A novel antiepileptic agent designed for improved efficacy and safety
Formulary , 12/16/09

Human genome sciences announces submission of marketing authorization application to emea for joulferon
Human Genome Sciences, 12/16/09

 See all of Drug/Product Approvals